238 related articles for article (PubMed ID: 37795778)
1. Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Pan B; Liang J; Shi H; Rao K; Guo W; Zhan C
Thorac Cancer; 2023 Nov; 14(33):3247-3258. PubMed ID: 37795778
[TBL] [Abstract][Full Text] [Related]
2. Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors.
Qin Y; Jian H; Tong X; Wu X; Wang F; Shao YW; Zhao X
Mol Oncol; 2020 Aug; 14(8):1695-1704. PubMed ID: 32412152
[TBL] [Abstract][Full Text] [Related]
3. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
Yang X; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
[TBL] [Abstract][Full Text] [Related]
4. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
[TBL] [Abstract][Full Text] [Related]
5. Mobocertinib (TAK-788): A Targeted Inhibitor of
Gonzalvez F; Vincent S; Baker TE; Gould AE; Li S; Wardwell SD; Nadworny S; Ning Y; Zhang S; Huang WS; Hu Y; Li F; Greenfield MT; Zech SG; Das B; Narasimhan NI; Clackson T; Dalgarno D; Shakespeare WC; Fitzgerald M; Chouitar J; Griffin RJ; Liu S; Wong KK; Zhu X; Rivera VM
Cancer Discov; 2021 Jul; 11(7):1672-1687. PubMed ID: 33632773
[TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
[TBL] [Abstract][Full Text] [Related]
7. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
Zhang W; Dong X
J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
[TBL] [Abstract][Full Text] [Related]
8. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
Hu M; Zhong C; Wang J; Chen J; Zhou T
Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
[TBL] [Abstract][Full Text] [Related]
9. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB
Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
11. Non-small cell lung cancer with
Kwon CS; Lin HM; Crossland V; Churchill EN; Curran E; Forsythe A; Tomaras D; Ou SI
Curr Med Res Opin; 2022 Aug; 38(8):1341-1350. PubMed ID: 35621011
[TBL] [Abstract][Full Text] [Related]
12. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
Hernandez L; Young M
J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
[No Abstract] [Full Text] [Related]
13. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
Bai Q; Wang J; Zhou X
Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
[TBL] [Abstract][Full Text] [Related]
14. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.
Shaffer W; Kobayashi IS; Sentana-Lledo D; Sundararaman S; Lee MD; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
Lung Cancer; 2023 Jul; 181():107250. PubMed ID: 37196448
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
[TBL] [Abstract][Full Text] [Related]
16. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
Russell MC; Garelli AM; Reeves DJ
Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
[TBL] [Abstract][Full Text] [Related]
17. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
Brazel D; Kroening G; Nagasaka M
BioDrugs; 2022 Nov; 36(6):717-729. PubMed ID: 36255589
[TBL] [Abstract][Full Text] [Related]
18. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
Sa H; Shi Y; Ding C; Ma K
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599
[TBL] [Abstract][Full Text] [Related]
19. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.
Lin YT; Liu YN; Wu SG; Yang JC; Shih JY
Clin Lung Cancer; 2017 May; 18(3):324-332.e1. PubMed ID: 28089594
[TBL] [Abstract][Full Text] [Related]
20. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with
Riely GJ; Neal JW; Camidge DR; Spira AI; Piotrowska Z; Costa DB; Tsao AS; Patel JD; Gadgeel SM; Bazhenova L; Zhu VW; West HL; Mekhail T; Gentzler RD; Nguyen D; Vincent S; Zhang S; Lin J; Bunn V; Jin S; Li S; Jänne PA
Cancer Discov; 2021 Jul; 11(7):1688-1699. PubMed ID: 33632775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
